Key Takeaways
- • Forus raised $150 million in Series C funding at a $3 billion valuation, led by Bain Capital Ventures with participation from 11 co-investors including Thrive Capital, General Catalyst, and Accel, bringing total raised to over $300 million.
- • The AI platform automates administrative workflows between prescribers, pharmacies, payers, and biopharma companies, addressing a critical bottleneck where one-third of patients prescribed high-cost or complex medications never fill their first dose.
- • Forus operates across all 50 U.S. states and reaches 85% of U.S. residential zip codes, with the company positioning itself as infrastructure for how new medicines reach patients in America.
- • The company plans to deploy capital toward three strategic priorities: expanding its AI agent and clinical model capabilities, broadening coverage across all medical specialties and care settings, and scaling technical and go-to-market teams.
- • CEO Sahir Jaggi highlighted that individual prescriptions require up to 15 coordination steps across insurance approvals, financial assistance, and pharmacy routing—a fragmented process Forus consolidates through a single AI-powered system per patient.
Summary
Forus, an AI platform previously known as Tandem, announced Tuesday a $150 million Series C funding round at a $3 billion valuation, signaling strong institutional confidence in its approach to automating pharmaceutical supply chain friction. The round was led by Bain Capital Ventures, which has backed the company since its seed stage, alongside 11 co-investors including Thrive Capital, General Catalyst, Accel, Redpoint Ventures, BoxGroup, Pear VC, Avra, Human Capital, Neo, Vast Ventures, and SV Angel. This latest raise brings Forus's total capital to over $300 million.
The platform operates at a critical juncture in pharmaceutical delivery: it connects doctors, pharmacies, payers, and biopharma companies to automate administrative workflows that currently impede patient access to newer treatments. According to Jaggi, approximately one-third of patients prescribed medications for high-cost or complex conditions never initiate their first dose, forcing providers to rely on older, more accessible therapies rather than newer medicines that may deliver superior clinical outcomes. A single prescription currently requires coordination across as many as 15 discrete steps—insurance approvals, financial assistance programs, specialty pharmacy routing, and fulfillment logistics—each varying by patient, drug, payer, and pharmacy. Forus consolidates this fragmented process by assigning an AI agent to each prescription that evaluates the patient's clinical, insurance, and financial circumstances and executes required actions to move patients from prescription through treatment initiation.
Forus has achieved significant operational scale, with providers in all 50 states using the platform to serve patients across 85% of U.S. residential zip codes. Kevin Zhang, general partner at Bain Capital Ventures, framed the investment as foundational infrastructure: "The next era of medicine will run on the AI-powered network Forus is building," emphasizing the company's evolution from a service provider to a systemic platform.
With the Series C proceeds, Forus will prioritize three deployment areas: deepening its platform through additional AI agents and clinical models, expanding coverage across all medical specialties and care sites, and scaling its technical and go-to-market teams. Jaggi articulated an expansive long-term vision: reducing development timelines, launch costs, and delivery predictability for biopharma should accelerate pharmaceutical investment in new medicines and indications. The company's stated goal is eventual penetration into every U.S. physician office, positioning Forus as foundational infrastructure for pharmaceutical distribution in the American healthcare system.
The platform operates at a critical juncture in pharmaceutical delivery: it connects doctors, pharmacies, payers, and biopharma companies to automate administrative workflows that currently impede patient access to newer treatments. According to Jaggi, approximately one-third of patients prescribed medications for high-cost or complex conditions never initiate their first dose, forcing providers to rely on older, more accessible therapies rather than newer medicines that may deliver superior clinical outcomes. A single prescription currently requires coordination across as many as 15 discrete steps—insurance approvals, financial assistance programs, specialty pharmacy routing, and fulfillment logistics—each varying by patient, drug, payer, and pharmacy. Forus consolidates this fragmented process by assigning an AI agent to each prescription that evaluates the patient's clinical, insurance, and financial circumstances and executes required actions to move patients from prescription through treatment initiation.
Forus has achieved significant operational scale, with providers in all 50 states using the platform to serve patients across 85% of U.S. residential zip codes. Kevin Zhang, general partner at Bain Capital Ventures, framed the investment as foundational infrastructure: "The next era of medicine will run on the AI-powered network Forus is building," emphasizing the company's evolution from a service provider to a systemic platform.
With the Series C proceeds, Forus will prioritize three deployment areas: deepening its platform through additional AI agents and clinical models, expanding coverage across all medical specialties and care sites, and scaling its technical and go-to-market teams. Jaggi articulated an expansive long-term vision: reducing development timelines, launch costs, and delivery predictability for biopharma should accelerate pharmaceutical investment in new medicines and indications. The company's stated goal is eventual penetration into every U.S. physician office, positioning Forus as foundational infrastructure for pharmaceutical distribution in the American healthcare system.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.